

LONSURF (trifluridine/tipiracil, oral)

Diagnosis Considered for Coverage:

- Appendiceal cancer – advanced or metastatic
- Colorectal cancer – advanced or metastatic
- Gastric or gastroesophageal junction adenocarcinoma - unresectable locally advanced, recurrent, or metastatic

Coverage Criteria:

For diagnosis of colon, rectal, or appendiceal cancer:

- Being used for advanced or metastatic disease, **and**
- Being used as subsequent therapy following previous systemic treatment for advanced or metastatic disease, **and**
- Being used as a single agent or in combination with bevacizumab, **and**
- Dose does not exceed 70 mg/m² based on trifluridine component per day on days 1-5, and days 8-12 given every 28 day cycle.

For gastric or gastroesophageal junction adenocarcinoma:

- Being used for unresectable locally advanced, recurrent, or metastatic disease, **and**
- Dose does not exceed 70 mg/m² based on trifluridine component per day on days 1-5, and days 8-12 given every 28 day cycle, **and**
- Being used as a single agent, **and**
- Being used as third-line or subsequent therapy.

Coverage Duration: one year

Effective Date: 02/28/2024